[1] SANTAMARIA A,NEEF R,EBERSPÄCHER U,et al.Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosi[J].Mol Biol Cell,2007,18:4024-4036.
[2] XU Y,CHEN X,LI Y.ERCC6L,a gene of SNF2 family,may play a role in the teratogenic action of alcohol[J].Toxicol Lett2005,157:233-239.
[3] BAUMANN C,KÖRNER R,HOFMANN K，et al.PICH,a centromere-associated SNF2 family ATPase,is regulated by Plk1 and required for the spindle checkpoint[J].2007,128(1):101-114.
[4] NIELSEN C F,HUTTNER D,BIZARD A H,et al.PICH promotes sister chromatid disjunction and co-operates with topoisomerase Ⅱ in mitosis[J].Nat Commun,2015,6:8962.
[5] EUN K K,EUI-JU C.Compromised MAPK signaling in human diseases:an update[J].Arch Toxicol,2015,89(6):867-882.
[6] PU S Y,YU Q,WU H,et al.ERCC6L,a DNA helicase,is involved in cell proliferation and associated with survival and progress in breast and kidney cancers[J].Oncotarget,2017,8(26):42116-42124
[7] CHEN H,WANG H X,YU X Q,et al.ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway[J].BMC Cancer,2020,20(1):853.
[8] FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-E386.
[9] YADA T,YOKOI C,UEMURA N.The current state of diagnosis and treatment for early gastric cancer[J].Diagn Ther Endosc,2013,2013:241320.
[10] WAGNER A D,GROTHE W,HAERTING J,et al.Chemotherapy in advanced gastric cancer:a systematic review and Meta-analysis based on aggregate data[J].J Clin Oncol,2006,24(18):2903-2909.
[11] CHEN D H,LIU Q H,CAO G.ERCC6L promotes cell growth and metastasis in gastric cancer through activating NF-κB signaling[J].Aging,2021,13(16):20218-20228.
[12] GREENBURG G,HAY E D.Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells[J].J Cell Biol,1982,95:333-339.
[13] NAWSHAD A,LAGAMBA D,POLAD A,et al.Transforming growth factor-beta signaling during epithelial-mesenchymal transformation:implications for embryogenesis and tumor metastasis[J].Cells Tissues Organs,2005,179(1-2):11-23.
[14] PAL S,BHATTACHARJEE A,ALI A,et al.Chronic inflammation and cancer:potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism[J].J Inflamm(Lond),2014,11:23.
[15] SÁNCHEZ-TILLÓ E,LIU Y,DE BARRIOS O,et al.EMT-activating transcription factors in cancer:beyond EMT and tumor invasiveness[J].Cell Mol Life Sci,2012,69(20):3429-3256.
[16] HE Z,DONG W,HU J,et al.AQP5 promotes hepatocellular carcinoma metastasis via NF-κB regulated epithelial-mesenchymal transition[J].Biochem Biophys Res Commun,2017,490(2):343-348.
[17] FERRARELLI L K.Treating WNT-driven colorectal cancer[J].Science,2017,356(6345):1346-1348.
[18] CHEN W,ZHENG R,ZENG H,et al.Annual report on status of cancer in China,2011[J].Chin J Cancer Res,2015,27(1):2-12.
[19] SIEGEL R L,MILLER K D,FEDEWA S A,et al.Colorectal cancer statistics,2017[J].CA Cancer J Clin,2017,67:177-193.
[20] FAN C,LIN Y,MAO Y,et al.MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS,MTA1 and HMGA2[J].Oncotarget,2016,7(16):21825-21839.
[21] XIE Y,YU J,WANG F,et al.ERCC6L promotes cell growth and invasion in human colorectal cancer[J].Oncol Lett,2019,18(1):237-246.
[22] BAINES A T,XU D AND DER C J.Inhibition of Ras for cancer treatment:the search continues[J].Future Med Chem,2011,3(14):1787-1808.
[23] SCLAFANI F,GULLO G,SHEAHAN K,et al.BRAF mutations in melanoma and colorectal cancer:a single oncogenic mutation with different tumour phenotypes and clinical implications[J].Crit Rev Oncol Hematol,2013,87(1):55-68.
[24] ZHANG J,ZHENG J,YANG Y,LU J,et al.Molecular spectrum of KRAS,NRAS,BRAF and PIK3CA mutations in Chinese colorectal cancer patients:analysis of 1,110 cases[J].Sci Rep,2015,5:18678.
[25] MCALLISTER F,BAILEY J M,ALSINA J,et al.Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia[J].Cancer Cell,2014,25(5):621-637.
[26] NGUYEN-NGOC T,BOUCHAAB H,ADJEI A A.BRAF alterations as therapeutic targets in non-small-cell lung cancer[J].J Thorac Oncol,2015,10:1396-1403.
[27] EL-SERAG H B,RUDOLPH K L.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology,2007,132(7):2557-2576.
[28] CUI C,FU K,YANG L,et al.Hypoxia inducible gene 2 promotes the immune escape of hepatocellular carcinoma from nature killer cells through the interleukin-10-STAT3 signaling pathway[J].J Exp Clin Cancer Res,2019,38(1):229.
[29] FORNER A,LLOVET JM,BRUIX J.Hepatocellular carcinoma[J].Lancet,2012,379(9822):1245-1255.
[30] KUZUYA T,ISHIGAMI M,ISHIZU Y,et al.Prognostic factors associated with postprogression survival in advanced hepatocellular carcinoma patients treated with Sorafenib not eligible for second-line Regorafenib treatment[J].Oncology,2018,95(2):91-99.
[31] BOSETTI C,TURATI F,LA VECCHIA C.Hepatocellular carcinoma epidemiology[J].Best Pract Res Clin Gastroenterol,2014,28(5):753-770.
[32] WANG X Q,BAI H M,LI S T,et al.Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells[J].Oncotarget,2017,8(29):48027-48040.
[33] FERLAY J S I,ERVIK M,DIKSHIT R,et al.GLOBOCAN 2012 v1.0,cancer incidence and mortality worldwide[EB/OL].[2023-10-02].https//www.scienceopen.com/document?vid=bb3caed1-db4b-4bc7-8194-eea2b547aad6.
[34] ZHANG G J，YU Z，FU S，et al.ERCC6L that is upregulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway[J].Cancer Gene Therapy,2019,26(9-10):323-333.
[35] TORRE L A,SIEGEL R L,WARD E M,et al.Global cancer incidence and mortality rates and trends-an update[J].Cancer Epidemiol Biomarkers Prev,2016,25(1):16-27.
[36] JOHANN D J,RODRIGUEZ-CANALES J,MUKHERJEE S,et al.Approaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry[J].J Proteome Res,2009,8(5):2310-2318.
[37] POLYAK K.Heterogeneity in breast cancer[J].J Clin Invest,2011,121(10):3786-3788.
[38] LIU J,SUN J,ZHANG Q,et al.shRNA knockdown of DNA helicase ERCC6L expression inhibits human breast cancer growth[J].Mol Med Rep,2018,18(3):3490-3496.
[39] FERLAY J,COLOMBET M,SOERJOMATARAM I,et al.Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods[J].Int J Cancer,2019,144(8):1941-1953.
[40] QUINTANAL-VILLALONGA Á,MOLINA-PINELO S.Epigenetics of lung cancer:a translational perspective[J].Cell Oncol(Dordr),2019,42(6):739-756.
[41] HUANG X Y,JIANG LY,LU S F,et al.Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma[J].Oncol Rep,2022,48(1):131.
[42] GAMAZON E R,STRANGER B E.The impact of human copy number variation on gene expression[J].Brief Funct Genomics,2015,14(5):352-357.
[43] GAO Y,TESCHENDORFF A E.Epigenetic and genetic deregulation in cancer target distinct signaling pathway domains[J].Nucleic Acids Res,2017,45(2):583-596.
[44] XIA C,DONG X,LI H,et al.Cancer statistics in China and United.States,2022:profiles,trends,and determinants[J].Chin Med J(Engl),2022,135(5):584-590.
[45] JOHNSON D E,BURTNESS B,LEEMANS C R,et al.Head and neck squamous cell carcinoma[J].Nat Rev Dis Prim,2020,6:92.
[46] ZHAO J,ZHANG P,WANG X.YBX1 promotes tumor progression via the PI3K/AKT signaling pathway in laryngeal squamous cell carcinoma[J].Transl Cancer Res,2021,10(11):4859-4869.
[47] CUI M,CHANG Y,WANG J H,et al.ERCC6L facilitates the progression of laryngeal squamous cell carcinoma by the binding of FOXM1 and KIF4A[J].Cell Death Discov，2023,9(1):41.
[48] MOLONEY J N,COTTER T G.ROS signalling in the biology of cancer[J].Semin Cell Dev Biol,2018,80:50-64.
[49] XU L,WU T,LU S,et al.Mitochondrial superoxide contributes to oxidative stress exacerbated by DNA damage response in RAD51-depleted ovarian cancer cells[J].Redox Biol,2020,36:101604.
[50] SCHUTZ C S,STOPE M B,BEKESCHUS S.H2A.X phosphorylation in oxidative stress and risk assessment in plasma medicine[J].Oxid Med Cell Longev,2021,2021:2060986.
[51] HU G,YAN Z,ZHANG C,et al.FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression[J].J Exp Clin Cancer Res,2019,38(1):188.
[52] BELLA L,ZONA S,NESTAL DE MORAES G,et al.FOXM1:a key oncofoetal transcription factor in health and disease[J].Semin Cancer Biol,2014,29:32-39. |
